T. Rowe Price Associates
AKYA

T. Rowe Price Associates’s Akoya BioSciences AKYA Stock Holding History

T. Rowe Price Associates’s Portfolio AKYA Stock Details AKYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,116
Closed -$19K – 3061
2025
Q1 		$19K Hold
13,116
– – ﹤0.01% 3006
2024
Q4 		$31K Buy
+13,116
New +$34.7K ﹤0.01% 2974
2021
Q3 		– Sell
-500,644
Closed -$9.68M – 2937
2021
Q2 		$9.68M Buy
+500,644
New +$10.3M ﹤0.01% 1422

Other funds holding AKYA

BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCA
Peddock Capital Advisors Braintree, Massachusetts $501M AUM 29.8% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

T. Rowe Price Associates's AKYA Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Akoya BioSciences (AKYA) in Q2 2025, closing a stake of 13,116 shares — an estimated $19K sold.

T. Rowe Price Associates first reported a position in AKYA in Q2 2021 and held it in 3 quarters. The position peaked at $9.68M in Q2 2021. 58 funds tracked by Wall St. Rank hold AKYA as of Q2 2025.

  • T. Rowe Price Associates reported no remaining Akoya BioSciences position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 13,116 Akoya BioSciences shares in Q2 2025, an estimated $19K.
  • T. Rowe Price Associates first reported a position in Akoya BioSciences in Q2 2021 and held it in 3 quarters.
  • T. Rowe Price Associates's Akoya BioSciences position peaked at $9.68M in Q2 2021.
  • 58 funds tracked by Wall St. Rank held Akoya BioSciences as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.